Conventional Chemotherapy and Oncogenic Pathway Targeting in Ovarian Carcinosarcoma Using a Patient-Derived Tumorgraft

Gretchen Glaser1, S. John Weroha2*, Marc A. Becker2, Xiaonan Hou2, Sergio Enderica-Gonzalez2, Sean C. Harrington2, Paul Haluska2

1 Division of Gynecologic Surgery, Mayo Clinic, Rochester, MN, United States of America, 2 Department of Oncology, Mayo Clinic, Rochester, MN, United States of America

These authors contributed equally to this work.

* weroha.saravut@mayo.edu

Abstract

Ovarian carcinosarcoma is a rare subtype of ovarian cancer with poor clinical outcomes. The low incidence of this disease makes accrual to large clinical trials challenging. However, studies have shown that treatment responses in patient-derived xenograft (PDX) models correlate with matched-patient responses in the clinic, supporting their use for preclinical testing of standard and novel therapies. An ovarian carcinosarcoma PDX is presented here-in and showed resistance to carboplatin and paclitaxel (similar to the patient) but exhibited significant sensitivity to ifosfamide and paclitaxel. The PDX demonstrated overexpression of EGFR mRNA and gene amplification by array comparative genomic hybridization (log2 ratio 0.399). EGFR phosphorylation was also detected. Angiogenesis and insulin-like growth factor pathways were also implicated by overexpression of VEGFC and IRS1. In order to improve response to chemotherapy, the PDX was treated with carboplatin/paclitaxel with or without a pan-HER and VEGF inhibitor (BMS-690514) but there was no tumor growth inhibition or improved animal survival, which may be explained by a KRAS mutation. Resistance was also observed when the IGF-1R inhibitor BMS-754807 was combined with carboplatin/ paclitaxel. Because poly (ADP-ribose) polymerase inhibitors have activity in ovarian cancer patients, with and without BRCA mutations, ABT-888 was also tested but found to have no activity. Pathogenic mutations were also detected in TP53 and PIK3CA. In conclusion, ifosfamide/paclitaxel was superior to carboplatin/paclitaxel in this ovarian carcinosarcoma PDX and gene overexpression or amplification alone was not sufficient to predict response to targeted therapy. Better predictive markers of response are needed.
Introduction

Ovarian cancer (OC) is the most lethal gynecologic malignancy, partly due to the lack of reliable screening methods and advanced stage at initial diagnosis. Ovarian carcinosarcoma (OCS), one of the most rare and aggressive forms of OC, remains extremely difficult to treat [1]. In the absence of randomized data, chemotherapy options for patients with OCS are based primarily on data from other ovarian and sarcoma subtypes, as well as retrospective data. Such studies have shown activity with platinum and taxane combinations [2–6]. Similarly, ifosfamide-based regimens have demonstrated clinical benefit in retrospective studies [7–9], with limited prospective phase II data [10]. Although the optimal chemotherapy regimen for OCS has not yet been defined, an ongoing front-line phase III study for uterine and ovarian carcinosarcomas (GOG-0261, NCT00954174) aims to determine which doublet combination, carboplatin/paclitaxel or ifosfamide/paclitaxel, is superior. However, it is likely that the response rates and survival benefit will continue to be inferior to that of epithelial OC, as it has been historically [6]. As such, novel therapies are needed in order to achieve better outcomes in OCS.

Targeting pathways like vascular endothelial growth factor (VEGF) and the epidermal growth factor (EGF) family (HER) may be beneficial in OCS [11, 12]. Given the rarity of OCS, there are limited data regarding the relevance of these pathways but when uterine carcinosarcoma tumors were analyzed for expression of potentially targetable genes, expression of EGFR and HER-2 was detected in 58.4% and 24.8% of samples (n = 101), respectively, while VEGF expression was found in 100% (n = 30) of patients [11, 13, 14]. In addition, VEGF targeting has demonstrated clinical benefit in large prospective randomized trials (GOG-0218 and ICON-7) of epithelial OC, but no such data exists for OCS [15, 16].

Less is known about the therapeutic role of insulin-like growth factor receptor-I (IGF-1R) inhibition in carcinosarcomas. However, in epithelial OC, the IGF-1R inhibitor BMS-754807 inhibits mesenchymal, epithelial, and hematopoietic tumor growth, and has activity in a xenograft model of epithelial OC [17, 18]. IGF targeting has not been described in OCS but overexpression of IGF-1R and IGF-II was reported in a uterine carcinosarcoma [12]. Thus, there is indirect evidence suggestive of IGF pathway involvement in OCS.

The incidence of OCS makes it difficult to determine the rate of BRCA1 and BRCA2 mutations in this disease. However, there is compelling evidence that BRCA-wildtype tumors can also demonstrate a BRCA-like phenotype, also referred to as BRCAness [19]. Indeed, measurable responses to olaparib, an inhibitor of poly (ADP-ribose) polymerase (PARP), were achieved in 24% of epithelial OC patients without known BRCA mutations [20]. The etiology of BRCAness is thought to involve the loss of other key genes required for homologous recombination (HR). Using massively parallel genomic sequencing, 4 of 12 OCS tumors demonstrated loss of function mutations in HR genes [21] and it is possible that PARP inhibition may be effective in this disease.

A barrier to achieving better clinical outcomes is the paucity of relevant animal models that recapitulate a patient’s response to therapy. In an effort to overcome this limitation, a biobank of common and rare OC patient-derived xenograft (PDX) models has been developed [22]. In this study, we present the differential response of an OCS to chemotherapy and explore the efficacy of combined targeted therapy.

Materials and Methods

Development of Carcinosarcoma Tumorgraft

Mayo Clinic Institutional Review Board (IRB) approved the collection of tissue from surgeries and approved the patient written consent form. Signed consent was scanned into the patient...
electronic medical record. Surgical tissue from a patient with ovarian carcinosarcoma was immediately taken to the research laboratory and issued a unique identifier in accordance with the Health Insurance Portability and Accountability Act. Tissues were processed as previously described for intraperitoneal establishment and viable storage of human OC tissue [22]. For each study, viably frozen tumorgraft tissue of patient heterotransplant #003 (PH003) was quickly thawed and washed several times in McCoy’s media. Minced OCS (0.1cm³ per mouse) was injected intraperitoneally.

All animal studies with female severe combined immunodeficient (SCID) mice (C.B.-17/IcrHsd-Prkdcsid Lystbg; Harlan Laboratories) were conducted with approval from, and in accordance with, the Mayo Clinic Institutional Animal Care and Use Committee, accredited by the American Association of Laboratory Animal Care, which meet or exceed the standards set by the U.S. Department of Agriculture Animal Welfare Act, Public Health Service policy on humane care and use of animals, and the NIH guide on laboratory animal welfare. Six- to nine-weeks old mice weighing 16–25 grams were housed in the Mayo Clinic Department of Comparative Medicine animal facility with less than 5 mice per pathogen-free cage. Access to standard rodent chow and water was *ad libitum*. Ambient light, temperature, and humidity were constantly controlled and bedding was routinely changed following standard protocols at Mayo Clinic.

**Efficacy of Cytotoxic Chemotherapy *in vivo***

Efficacy of carboplatin/paclitaxel (C/P) and ifosfamide/paclitaxel (I/P) were directly compared. PH003 was injected into SCID mice and subsequently randomized into three groups for intraperitoneal treatment (n = 13 each): control (saline treatment), C/P (64 and 19 mg/kg, respectively), or I/P (116 and 29 mg/kg, respectively). C/P mice were treated with three weekly doses of carboplatin and paclitaxel while the I/P cohort received three weekly doses of ifosfamide and paclitaxel and two additional daily treatments of single-agent ifosfamide following each doublet, as conducted in GOG-0261 (NCT00954174). For all *in vivo* studies, animals were assessed at least five days per week and a health score was derived from appearance, behavior, and body conditioning as described [23]. Scores ≤6 met criteria for moribund and mice were sacrificed by carbon dioxide inhalation.

**Phosphotyrosine Kinase Blot Array**

Receptor tyrosine kinase (RTK) phosphorylation was assessed in snap-frozen tumorgraft tissue and cell culture lysates using the Human Proteome Profiler Array (#ARY001, R&D Systems) following the manufacturers standard protocol. Proteins were extracted with 1% NP-40 lysis buffer containing fresh protease and phosphatase inhibitors (Sigma-Aldrich, St. Louis, MO Cat# P8340 and #P5726) with disruption (tumorgraft tissue only) in a VirTis Ultrasonic Cell Disrupter 100 (The VirTis Company, Gardiner NY). Protein concentration was determined by BCA Reagents (Thermo Scientific, Waltham, MA) and 50 micrograms of protein was applied to blot arrays overnight at 4°C with agitation. The anti-Phospho-Tyrosine-HRP Detection Antibody was applied for 2hrs at room temperature with agitation and expression was visualized with Chemi Reagent Mix, provided in the kit. Blots were simultaneous exposure to the same x-ray film. Signals were analyzed using ImageJ 1.47v to quantify dot intensity peaks using the rolling-ball method for background subtraction [24]. Blots lacked a housekeeping gene for normalization so only intra-blot relative phospho-protein expression was compared.

**Array Comparative Genomic Hybridization**

Array comparative genomic hybridization (aCGH) was performed using the Agilent Human Genome CGH microarray kit 244A with matched-patient reference germline DNA as
previously described [22]. Tumorgraft DNA was extracted following the manufacturers protocol for Qiagen AllPrep DNA/RNA mini Kit (#80204) and quantitated on a Thermo Scientific NanoDrop 2000c UV-Vis Spectrophotometer. Test (tumor) and reference (matched patient germline) DNA was labeled with Cy5 and Cy3, respectively, by random priming PCR, hybridized over 24 hrs at 65°C, and analyzed with Agilent Technologies Genomic Workbench 6.5 Lite Edition software. Gains and losses were defined as >4 regional probes with an absolute average log ratio of ≥0.26 for the region.

**Quantitative Polymerase Chain Reaction (QPCR)**

To validate copy number aberrations detected by aCGH, tumor and matched patient germline DNA were analyzed by QPCR. *EGFR* primers (Set 1, FW 5’-ccttgccacctttctgc-3’ and REV 5’-tcaggaagcagtcttttg-3’; Set 2 FW 5’-GGGCAAAGAAGAAACGGAG-3’ and REV 5’-GTCCATCAGTGGGGAGTAAG-3’) were used to amplify 10 ng of genomic DNA in a LightCycler 480 II (Roche Life Science, Indianapolis, IN) with SYBR green as the detection method. Rather than use a single locus as the reference for calculation of ΔΔCT, a multi-copy locus primer kit (Type-it CNV SYBR Green PCR, Cat# 206672) from Qiagen was used to minimize the impact of genome-wide gains and losses expected in tumor DNA. The ratio (R) of the copy number change of *EGFR* in tumor DNA compared to matched germline DNA was calculated by 

\[ R = 2^{\Delta \Delta CT} \]

where \( \Delta \Delta CT = \Delta CT \text{ (Tumor DNA)} - \Delta CT \text{ (Germline DNA)} = (CT \text{ (EGFR, Tumor DNA)} - CT \text{ (Reference, Tumor DNA)}) - (CT \text{ (EGFR, Germline DNA)} - CT \text{ (Reference, Germline DNA)}) \). An R > 1 indicates a higher copy number of *EGFR* in the tumor DNA relative to germline.

**Pathway-directed Therapeutics**

PH003 OCS was heterotransplanted into SCID mice (n = 13 each cohort) and treated with C/P alone or in combination with either EVRI (pan-HER and VEGF inhibitor, BMS 690514), IGF-1Ri (IGF-1R inhibitor, BMS 754807) or PARPi (poly ADP-ribose polymerase inhibitor, ABT-888). All targeted therapies were purchased from Selleck Chemicals, Houston, TX. EVRI (50 mg/kg) and IGF-1Ri (50mg/kg) was diluted and administered by daily oral gavage as previously described [25, 26] and ABT-888 (25 mg/kg in PEG400:water, 80:20) was administered by daily oral gavage on days 1–3, 8–10, and 15–17. The dose of ABT-888 was chosen based on previous in vivo data showing potentiation of chemotherapy at 25 mg/kg/day [27]. However, ensure animals could tolerate a longer treatment course, the schedule was modified to intermittent dosing, which is a dosing schedule used in an ongoing clinical trial in ovarian cancer at Mayo Clinic (NCT01012817).

**Western Blots**

Protein extraction and blotting was performed as previously described [28]. Tumor tissue was homogenized in buffer containing 50 mM Tris (pH 7.4), 1 mM EDTA, 150 mM NaCl and proteinase inhibitors (1 μg/ml phenylmethylsulfonyl fluoride, 10 μg/ml aprotinin and 1μg/ml leupeptin). The homogenates were centrifuged at 2,000g for 15 min and 10,000g for 5 min prior to determining concentration using BCA Reagents. Proteins were separated by 10% SDS-PAGE electrophoresis and transferred to Immuno-Blot polyvinylidene difluoride (PVDF) membranes (Bio-Rad, Cat#: 162–0177). The membranes were blocked with 5% milk in TBS (10 mM Tris-HCl pH 8.0 and 150 mM NaCl) plus 0.05% Tween-20 for 1 hour and then incubated with primary antibodies in 5% milk overnight at 4°C. After washing, blots were incubated with HRP-conjugated secondary antibodies in 5% milk for 1 hour at room temperature. The
bands were detected using an ECL kit (Amersham, Arlington Heights, IL) and visualized on x-ray film.

All antibodies were commercially available. Monoclonal anti-PAR polymer antibody (#4335-MC-100-AC, Trevigen, Gaithersburg, MD) was used at 1:1000. Rabbit polyclonal anti-total Akt antibody (#9272, Cell Signaling, Danvers, MA) was diluted 1:1000 and anti-phospho-Akt antibody (#9271, Cell Signaling) was diluted 1:2000. Mouse monoclonal anti-actin antibody (#A3853, Sigma-Aldrich, St. Louis, MO) was used at 1:1000. Anti-mouse (#074–1806) or anti-rabbit (#074-15-061) secondary antibodies were used at 1:2000 (KPL Inc., Gaithersburg, MD).

Next Generation Sequencing and Bioinformatics

Genomic DNA from fresh untreated PDX tissue was extracted as described above for aCGH. Samples were enriched using the Ion AmpliSeq Cancer Hotspot Panel (Life Technologies, Grand Island, NY) and prepped using the TruSeq Nano Library prep (Illumina, San Diego, CA) before sequencing as Paired End 150 reads on the Illumina MiSeq. To account for mouse genomic DNA, the Xenome tool [29] was used to classify sequence read data as either human or mouse genome. Only the human paired-end Illumina reads were analyzed using Genome_GPS, an analysis pipeline for DNA sequencing data at Mayo Clinic. Raw FASTQ formatted reads were aligned using bwa-mem version 0.7.10 [30] against reference genome (hg19), and the aligned Sequence Alignment Map (SAM) files were converted to a coordinate sorted binary SAM (BAM) file using SAMtools 0.1.19 [31]. The BAM files were then processed through Genome Analysis Toolkit 2.7 (GATK, Broad Institute, Cambridge, MA, USA). The raw variants were called using GATK’s UnifiedGenotyper walker version 2.7 with default parameters. Significant variants were called if the effect was non-synonymous and contained ≥249 high quality reads.

Statistical Analysis

The sample sizes in each in vivo study had 89% power to detect a 20% difference in mean tumor mass between control and treated animals. Survival curve differences were analyzed by log-rank test with significance defined by \( p < 0.05 \). To analyze group data, differences were determined using the Student’s t test (two tailed) or ANOVA with \( p \leq 0.05 \) considered statistically significant. Pearson’s correlation was used to assess association between continuous variables.

Results

Defining the Maximum Tolerated Dose of Chemotherapy

Although dose and schedule for targeted therapies were chosen based on published literature, the maximum tolerated dose of intraperitoneal carboplatin/paclitaxel (C/P) or ifosfamide/paclitaxel (I/P) was not well defined. Mice bearing palpable tumors were divided into two arms (\( n = 4 \) each) and treated with intraperitoneal C/P or I/P at starting doses reported in the literature for mono-therapy and adjusted to account for their simultaneous administration [32–36] (Table 1). The maximum tolerated dose was determined using a standard ‘3 + 3’ design commonly utilized in phase 1 clinical trials [37]. Dose-limiting toxicity (DLT) was defined as a treatment dose that resulted in a health score of \( \leq 6 \) or weight loss greater than 20% of baseline. For the C/P group, one mouse developed a DLT at level two and after expansion to a total of seven mice, additional DTL was observed and only dose level 1 was deemed tolerable at 64 mg/kg carboplatin and 19 mg/kg paclitaxel. For the I/P group, no DTLs were observed in >1
mouse at any dose level so 116 mg/kg ifosfamide and 29 mg/kg paclitaxel (level 3) was deemed tolerable.

**Histologic Evaluation of Tumor Tissue**

To determine the histologic similarity between the PH003 patient and PDX tumor tissue, hematoxylin and eosin staining was performed on formalin-fixed, paraffin embedded 5–6 μm sections. Two different source tumor regions were examined and exhibited variability in contribution from mesenchymal and carcinoma components (Fig 1A and 1B). Four different PH003 xenografts were examined and representative images (Fig 1C and 1D) show a closer resemblance to the confluent carcinoma pattern of the patient (Fig 1B).

**Semi-Quantitative Assessment of Tumor Size in vivo**

OCS model PH003 tends to form a discrete mass(s) rather than carcinomatosis, making assessment of intra-abdominal tumor burden possible by direct palpation. Since serial in vivo assessment of intraperitoneal tumor size is difficult by caliper measurements, a semi-quantitative study was conducted to determine the utility of an abdominal-pelvic tumor palpation scoring system, based on the palpable tumor size relative to the mouse hemi-pelvis: zero = non-palpable, 1 is < 25%, 2 is 26–49%, and 3 is >50% (Fig 2A). When tumor diameter was scored prior to necropsy and compared with post-necropsy tumor weight, strong correlation was observed (Pearson r = 0.8965, two-tailed p < 0.0001 (Fig 2B).

**Response to Cytotoxic Chemotherapy in vivo**

When engraftment was evident by palpation, mice were randomized to receive saline control, C/P, or I/P at doses defined above. The primary endpoint was tumor mass at necropsy but overall survival and tumor palpation score were recorded as secondary endpoints. All mice had a health score [23] of 11+ on day one and were sacrificed at a score ≤6 or if they had greater than 20% weight loss. Due to rapid growth of OCS PH003, control mice were moribund by treatment-day 7 (Fig 3A). Animals treated with C/P exhibited improved median survival to

---

**Table 1. Dosing algorithms for dose finding portion of study.**

| Dose Level | Carboplatin mg/kg | Paclitaxel mg/kg |
|------------|-------------------|------------------|
| 0          | 51                | 15               |
| 1*         | 64                | 19               |
| 2          | 80                | 24               |
| 3          | 96                | 29               |

| Dose Level | Ifosfamide mg/kg | Paclitaxel mg/kg |
|------------|------------------|------------------|
| -1         | 64 Day 1         | 15               |
| 0          | 80 Day 1         | 19               |
| 1*         | 80 Day 1,2,3     | 19               |
| 2          | 96 Day 1,2,3     | 24               |
| 3          | 116 Day 1,2,3    | 29               |

*Starting dose level

doi:10.1371/journal.pone.0126867.t001
13.5 days while the I/P cohort had only one moribund animal during the study period and the median survival was not reached. The difference between treatment arms was significant (log-rank test, p = 0.0027). The serial decline in palpation scores observed with I/P treatment was consistent with improved survival, indicating tumor regression over time (Fig 3B). The stable palpation score seen in the C/P-treated group was also consistent with survival data as moribund mice with larger tumors were sacrificed over time. When normalized to the mean control tumor mass measured at necropsy (day 7), the difference in final tumor mass at necropsy between C/P (0.44 +/-0.078) and I/P (0.059 +/- 0.016) cohorts was significant (p < 0.0001, two-tailed t test) (Fig 3C).

Activation of Oncogenic Pathways

Since platinum-based doublet chemotherapy is a standard of care for OCS and the observed in vivo response to C/P was inferior to I/P, exploratory analysis of oncogenic pathways was performed in order to find potentially targetable pathways with an ultimate goal of augmenting treatment efficacy with C/P. An RTK array was performed to assess for phosphorylated RTKs in actively proliferating untreated control PDX tissue. Representative images are shown for...
pathways relevant to OCS: the epidermal growth factor family, vascular endothelial growth factor receptor, and insulin-like growth factor receptor 1 (Fig 4A). PDX tissue showed a disproportionately higher level of phosphorylated HER family of receptors, EGFR in particular, suggesting a potential role for HER inhibition in vivo. In the absence of a relevant control tissue, PH003 PDX tissue was minced and passed through a cell strainer for short-term culture and the RTK phosphorylation profile was assessed during serum-starvation (serum-free McCoy’s media for 24 hours prior to harvest) and after overnight starvation followed by 15 minutes of complete media prior to harvest. The proportion of phosphorylated RTKs remained largely unchanged between serum-starved and serum-fed states (Fig 4A and 4B), suggesting a potential role for EGFR activation in vivo but not in vitro. To compile additional evidence to support HER targeting, Affymetrix microarray data was queried from 36 tumorgraft models,

Fig 2. Correlation of abdominal palpation score and tumor weight at necropsy. (A) The palpation score was based on tumor size relative to the mouse hemi-pelvis. (B) Palpation score prior to necropsy correlated with tumor weight at necropsy (Pearson r = 0.8965, two-tailed p <0.0001).

doi:10.1371/journal.pone.0126867.g002

Fig 3. Tumorgraft response to treatment in vivo. Mice were randomized to receive (n = 13 each group) either saline, carboplatin and paclitaxel (C/P), or ifosfamide and paclitaxel (I/P). (A) Kaplan-Meier Curve demonstrates survival. The C/P and I/P curves were significantly different, log-rank test p = 0.0027. (B) Tumor palpation score over time reflects the change in tumor size with treatment. (C) Tumor weights in each cohort were normalized against the final mean control weight obtained at necropsy on day 7 (which represents the maximum-allowed tumor burden). The difference between C/P and I/P relative tumor mass was significant (two-tailed t test, p <0.0001).

doi:10.1371/journal.pone.0126867.g003
including PH003, which was previously reported [38] and publically available (Gene Expression Omnibus # GSE66667). PH003 PDX was found to have the highest relative expression of EGFR (Fig 4C). In addition, aCGH showed amplification of chromosome 7p, containing EGFR with a log2 ratio of 0.399, or a 1.32-fold change in tumor DNA relative to germline DNA (Fig 4D). This amplification was validated by QPCR using two separate EGFR primers showing a mean 1.26-fold (+/- 0.042 SE) difference in EGFR copy number relative to the source patient germline DNA. A balance of Red and Green probes signifies equal representation of tumor and germline DNA in the q arm. The p arm shows an unbalanced representation of tumor genomic DNA (log2 ratio 0.399 compared to germline). The bold vertical jagged line shows the average log2 ratio of tumor and germline DNA along chromosome 7.

Fig 4. Potential targets of novel therapies. (A) Receptor tyrosine kinase (RTK) dot blot array. Goat IgG and phosphate buffered saline (PBS) are background controls. Each RTK is blotted in duplicate. (B) The proportion of signal contributed by select RTKs in serum free media (SFM), complete media (CM), and in tissues harvested after engraftment in a mouse (in vivo). (C) Microarray analysis for expression of EGFR, VEGF, and IRS1 in model PH003 (red shape) and 35 other ovarian patient-derived tumorgraft models (black shapes). (D) Array comparative genomic hybridization showing chromosome 7. Red dots represent probes from the tumor genome and Green dots represent probes from the patient’s germline DNA. A balance of Red and Green probes signifies equal representation of tumor and germline DNA in the q arm. The p arm shows an unbalanced representation of tumor genomic DNA (log2 ratio 0.399 compared to germline). The bold vertical jagged line shows the average log2 ratio of tumor and germline DNA along chromosome 7.

doi:10.1371/journal.pone.0126867.g004
Given the preliminary evidence for activity of PARP inhibitors in both BRCA mutant and wild-type ovarian cancer, we evaluated PARP inhibition [39, 40]. However, given the lack of responsiveness of the source patient to platinum—based chemotherapy and lack of markers by aCGH and DNA microarray to suggest deficiencies in homologous recombination, our hypothesis was that PH003 would lack responsiveness.

**Efficacy of Concomitant Cytotoxic and Targeted Therapy**

Since the *in vivo* response to C/P was significantly inferior to I/P, the concomitant use of targeted therapy was tested. Mice were heterotransplanted with OCS tumorgraft tissue as above and after palpable tumors were present, randomization occurred into one of four cohorts, n = 13 each: C/P alone, C/P + EVRI, C/P + IGF-1Ri, or C/P + PARPi. The rationale for using EVRI (pan-HER and VEGF inhibitor) was based on previous work showing improved efficacy with dual-pathway targeting in a xenograft model of epithelial OC [25]. Primary and secondary endpoints were tumor mass at necropsy and overall survival, respectively. No combination therapy significantly extended survival relative to C/P alone (Fig 5A). In addition, there were
no differences in final tumor weight relative to C/P at necropsy (one-way ANOVA with Dunnett’s Multiple Comparisons, p >0.05) (Fig 5B).

To explore the potential reasons for this lack of response, post-treatment tumor tissue was analyzed by Western blot for downstream markers of on-target effects. With regard to PARP inhibition, ABT-888 effectively inhibited PAR polymer formation in PH003 PDX tissue (Fig 5C). Treatment with EVRI or IGR-1Ri resulted in downregulation of p-AKT relative to chemotherapy-only controls (Fig 5D). Since mutations may confer resistance to targeted therapies, next-generation sequencing of select genes was performed. PH003 exhibited a non-synonymous KRAS mutation at c.35G>A (p.Gly12Asp based on RefSeq NM_004985, rs121913529). In addition, a pathogenic mutation in PIK3CA (c.1258T>C) was discovered (p.Cys420Arg based on RefSeq NM_006218, rs121913272). Although a stop codon was detected in PTEN, the tumor was homozygous for this mutation and the biological significance is uncertain (S1 Table). A mutation in CTNNB1 was also detected but the read depth fell below our threshold for significance. A TP53 mutation was also discovered at c.347G>A (p.Arg116Gln based on RefSeq NM_001126115, rs11540652).

Discussion

Ovarian carcinosarcoma is one of the least common but most aggressive forms of OC with no prospective, randomized data to define a standard chemotherapy treatment. This is largely due to the rarity of OCS, which imposes significant challenges with regard to patient accrual to clinical trials [36]. To address such challenges, an ongoing project to collect and characterize rare and common OC tumor types is underway [22]. The first in vivo efficacy studies of an OCS tumorgraft is reported herein. We show that I/P was superior to C/P in this OCS model and there was limited efficacy of rationally-selected targeted therapies.

With a single OCS model, the current study was not designed to show superiority of C/P or I/P in ovarian carcinosarcomas. However, it has been shown that in vivo patient-derived xenograft responses to therapy correlate to the matched patient experience [22, 41, 42]; such models provide an opportunity to compare the efficacy of different chemotherapy combinations in individual PDX models, and by extension, in individual patient. Although its unknown if I/P would have been more effective in the patient from which PH003 was derived, the patient was treated with C/P and developed bone metastases within two months of the last carboplatin/paclitaxel dose, indicative of chemotherapy resistance and consistent with the PH003 PDX response.

Since the overall prognosis for OCS is inferior to other ovarian cancers treated with standard chemotherapy, novel targeted agents are needed. In this study, a rationalized approach to drug selection was attempted. However, the lack of response to inhibitors of EGFR, VEGFR, IGF-1R, and PARP indicates that gene expression and amplification profiling alone are not sufficient to predict response. Indeed, further molecular characterization showed that PH003 harbors a KRAS mutation in codon 12, p.Gly12Asp, which was previously described in lung [43] and colon cancers [44], and is associated with decreased efficacy of EGFR inhibitors afatinib and gefitinib [45]. As such, p.Gly12Asp may explain the lack of response from EVRI. Mutations reported herein for KRAS, PIK3CA, and TP53 are consistent with previous studies on patient samples [46] and supports the clinical relevance of this OCS model.

Assessment of intraperitoneal in vivo tumor response during treatment is central to PDX-based studies. Although techniques such as ultrasound [22] and bioluminescence [25] are well established, such methods require specialized training and/or equipment. Alternatively, the current study supports the use of a physical-exam based scoring method to supplement final tumor weight and animal survival as endpoints.
The histologic characteristics of common ovarian patient-derived xenograft subtypes (e.g., serous and endometrioid) have been described previously [22, 42, 47–52] but there is a paucity of PDX models for OCS. The PH003 PDX shows a predominately carcinomatous pattern with less contribution from mesenchymal components when compared to the source tumor. Similar histologic observations were also seen in another OCS PDX model, JoN xenografts [53]. However, JoN xenografts were developed with an interim *in vitro* culturing step prior to heterotransplantation in mice and it is possible that the sarcomatous components were selectively excluded. Since PH003 was directly heterotransplanted and the stromal components of xenograft tissue are derived from the murine host [22], the rapid growth of PH003 may not permit concurrent outgrowth of the mesenchymal component.

As interest continues to grow for the utilization of patient-derived tumor xenografts (tumorgrafts) in drug development [54], there is hope for the identification of novel therapies in rare cancers such as OCS. Model PH003, and future OCS tumorgraft models, may be helpful in this regard as the number of rare ovarian tumorgrafts continue to grow in the Mayo Clinic ovarian cancer PDX bank [22].

**Supporting Information**

S1 Table. Next-generation DNA sequencing results of tumorgraft tissue, sorted by read depth. CHROM: The chromosome; POS: The reference position, with the 1st base having position 1; DP: Approximate read depth; some reads may have been filtered; QUAL: Phred-scaled quality score for the assertion made in ALT using formula \(-10\log_{10}P\) where \(P\) = base-calling error probability. REF: The reference base; ALT: alternate non-reference allele; AF: allele frequency in the sample; NSC: non-synonymous coding. * Stop codon gained.

(DOCX)

**Author Contributions**

Conceived and designed the experiments: GG SJW MAB SE SCH XH PH. Performed the experiments: GG SJW MAB SE SCH XH. Analyzed the data: GG SJW MAB SE SCH XH PH. Contributed reagents/materials/analysis tools: GG SJW MAB SE SCH XH PH. Wrote the paper: GG SJW MAB SE SCH XH PH.

**References**

1. Jernigan AM, Fader AN, Nutter B, Rose P, Tseng JH, Escobar PF. Ovarian carcinosarcoma: effects of cytoreductive status and platinum-based chemotherapy on survival. Obstet Gynecol Int. 2013; 2013:490508. Epub 2013/06/20. doi: 10.1155/2013/490508 PMID: 23781249; PubMed Central PMCID: PMC3678456.

2. Loizzi V, Cormio G, Camporeale A, Falagario M, De Mitri P, Scardigno D, et al. Carcinosarcoma of the ovary: analysis of 13 cases and review of the literature. Oncology. 2011; 80(1–2):102–6. Epub 2011/06/17. doi: 10.1159/000328794000328794 [pii]. PMID:21677454.

3. Leiser AL, Chi DS, Ishill NM, Tew WP. Carcinosarcoma of the ovary treated with platinum and taxane: the memorial Sloan-Kettering Cancer Center experience. Gynecol Oncol. 2007; 105(3):657–61. Epub 2007/03/31. S0090-8258(07)00094-7 [pii] doi: 10.1016/j.ygyno.2007.01.037 PMID: 17395252.

4. Inthasorn P, Beale P, Dairymple C, Carter J. Malignant mixed mullerian tumour of the ovary: prognostic factor and response of adjuvant platinum-based chemotherapy. Aust N Z J Obstet Gynaecol. 2003; 43 (1):61–4. Epub 2003/05/21. PMID: 12755391.

5. Duska LR, Garrett A, Eltabbakh GH, Oliva E, Benson R, Fuller AF. Paclitaxel and platinum chemotherapy for malignant mixed mullerian tumors of the ovary. Gynecol Oncol. 2002; 85(3):459–63. Epub 2002/06/08. S0090-8258(02)00664X [pii] doi: 10.1016/S0090-8258(02)00664-X PMID: 12051674.

6. Rauh-Hain JA, Growdon WB, Rodriguez N, Goodman AK, Boruta DM 2nd, Schorge JO, et al. Carcinosarcoma of the ovary: a case-control study. Gynecol Oncol. 2011; 121(3):477–81. Epub 2011/03/23. doi: 10.1016/j.ygyno.2011.02.023 PMID: 21420726.
7. Crotzer DR, Wolf JK, Gano JB, Gershenson DM, Levenback C. A pilot study of cisplatin, ifosfamide and mesna in the treatment of malignant mixed mesodermal tumors of the ovary. Gynecol Oncol. 2007; 105(2):399–403. Epub 2007/02/13. S0090-8258(06)01039-0 [pii] doi: 10.1016/j.ygyno.2006.12.023 PMID: 17292457.

8. Rutledge TL, Gold MA, McMeekin DS, Huh WK, Powell MA, Lewin SN, et al. Carcinosarcoma of the ovary—a case series. Gynecol Oncol. 2006; 100(1):128–32. Epub 2005/10/11. doi: 10.1016/j.ygyno.2005.07.119 PMID: 16213011.

9. Sit AS, Price FV, Kelley JL, Comerci JT, Kunschner AJ, Kanbour-Shakir A, et al. Chemotherapy for malignant mixed Mullerian tumors of the ovary. Gynecol Oncol. 2000; 79(2):196–200. Epub 2000/11/07. doi: 10.1006/gyno.2000.5956 PMID: 11063643.

10. Sutton GP, Blessing JA, Homesley HD, Malfetano JH. A phase II trial of ifosfamide and mesna in patients with advanced or recurrent mixed mesodermal tumors of the ovary previously treated with platinum-based chemotherapy: a Gynecologic Oncology Group Study. Gynecol Oncol. 1994; 53(1):24–6. Epub 1994/04/01. S0090-8258(94)71081-X [pii] doi: 10.1006/gyno.1994.1061 PMID: 8175017.

11. Cimbalka D, Rotmensch J, Scudiere J, Gown A, Bitterman P. Uterine carcinosarcoma: immunohistochemical studies on tissue microarrays with focus on potential therapeutic targets. Gynecol Oncol. 2006; 100(1):101–6. Epub 2005/09/15. doi: 10.1016/j.ygyno.2005.07.124 PMID: 16157366.

12. Roy RN, Gerulath AH, Cecutti A, Bhavnani BR. Loss of IGF-II imprinting in endometrial tumors: overexpression in carcinosarcoma. Cancer Lett. 2000; 153(1–2):67–73. Epub 2000/04/26. PMID: 10779632.

13. Sawada M, Tsuda H, Kimura M, Okamoto S, Kita T, Kasamatsu T, et al. Different expression patterns of KIT, EGFR, and HER-2 (c-erbB-2) oncoproteins between epithelial and mesenchymal components in uterine carcinosarcoma. Cancer Sci. 2003; 94(11):986–91. Epub 2003/11/13. PMID: 14611676.

14. Livasy CA, Reading FC, Moore DT, Boggess JF, Lininger RA. EGFR expression and HER2/neu overexpression/amplification in endometrial carcinosarcoma. Gynecol Oncol. 2006; 100(1):101–6. Epub 2005/09/15. doi: 10.1016/j.ygyno.2005.07.124 PMID: 16157366.

15. Perren TJ, Swart AM, Pfisterer J, Ledermann JA, Pujade-Lauraine E, Kristensen G, et al. A phase 3 trial of bevacizumab in ovarian carcinoma. N Engl J Med. 2011; 365(26):2484–96. Epub 2011/12/30. doi: 10.1056/NEJMoa1104390 PMID: 22204725.

16. Burger RA, Brady MF, Bookman MA, Fleming GF, Monk BJ, Huang H, et al. Incorporation of bevacizumab in ovarian cancer. N Engl J Med. 2011; 365(26):2484–96. Epub 2011/12/30. doi: 10.1056/NEJMoa1104390 PMID: 22204725.

17. Rigakos G, Razis E. BRCAness: finding the Achilles heel in ovarian cancer. Oncologist. 2012; 17(3):443–53. Epub 2012/02/29. doi: 10.1634/theoncologist.2012-008176 PMID: 22336899.

18. Weroha SJ, Haluska P. IGF-1 receptor inhibitors in clinical trials—early lessons. J Mammary Gland Biol Neoplasia. 2008; 13(4):471–83. Epub 2008/11/22. doi: 10.1007/s10911-008-9104-6 PMID: 19023648; PubMed Central PMCID: PMC2728362.

19. Rigakos G, Razis E. BRCAness: finding the Achilles heel in ovarian cancer. Oncologist. 2012; 17(7):956–62. Epub 2012/06/08. doi: 10.1634/theoncologist.2012-00281 PMID: 22673632; PubMed Central PMCID: PMC3393652.

20. Gelmon KA, Tischkowitz M, Mackay H, Swenerton K, Robidoux A, Tonkin K, et al. Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study. Lancet Oncol. 2011; 12(8):852–61. Epub 2011/08/25. doi: 10.1016/s1470-2045(11)70214-5 PMID: 21862407.

21. Pennington KP, Walsh T, Harrell MI, Lee MK, Pennil CC, Rendi MH, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014; 20(3):764–75. Epub 2013/11/19. doi: 10.1158/1078-0432.CCR-13-2287 PMID: 24240112; PubMed Central PMCID: PMC3944197.

22. Weroha SJ, Becker MA, Enderica-Gonzalez S, Harrington SC, Oberg AL, Maurer MJ, et al. Tumorgrafts as in vivo surrogates for women with ovarian cancer. Clin Cancer Res. 2014; 20(5):1288–97. Epub 2014/01/09. doi: 10.1158/1078-0432.CCR-13-2611078-0432.CCR-13-2611 [pii] PMID: 24398046; PubMed Central PMCID: PMC3947430.

23. Paster EV, Villines KA, Hickman DL. Endpoints for mouse abdominal tumor models: refinement of current criteria. Comp Med. 2009; 59(3):234–41. Epub 2009/07/22. PMID: 19619413; PubMed Central PMCID: PMC2733284.

24. Schneider CA, Rasband WS, Eliceiri KW. NIH Image to ImageJ: 25 years of image analysis. Nat Methods. 2012; 9(7):671–5. Epub 2012/08/30. PMID: 22930834.
25. Nemati F, Livartowski A, De Cremoux P, Bourgeois Y, Arvelo F, Pouillart P, et al. Distinctive potentiation of in vivo ovarian cancer tumor growth. Mol Cancer Ther. 2013; 12(12):2909–16. Epub 2013/10/17. doi: 10.1158/1535-7163.MCT-13-05471535-7163.MCT-13-0547 [pii]. PMID: 24130556; PubMed Central PMCID: PMC3880137.

26. Hou X, Huang F, Macedo LF, Harrington SC, Reeves KA, Greer A, et al. Dual IGF-1R/InsR inhibitor BMS-754807 synergizes with hormonal agents in treatment of estrogen-dependent breast cancer. Cancer Res. 2011; 71(24):7597–607. Epub 2011/11/02. doi: 10.1158/0008-5472.CAN-11-1080 PMID: 22042792.

27. Palma JP, Wang YC, Rodriguez LE, Montgomery D, Ellis PA, Bukofzer G, et al. ABT-888 confers broad in vivo activity in combination with temozolomide in diverse tumors. Clin Cancer Res. 2009; 15(23):7277–90. Epub 2009/11/26. doi: 10.1158/1078-0432.CCR-09-1245 PMID: 19934293.

28. Haluska P, Carboroni JM, TenEyck C, Attar RM, Hou X, Yu C, et al. HER receptor signaling confers resistance to the insulin-like growth factor-I receptor inhibitor, BMS-536924. Molecular cancer therapeutics. 2008; 7(9):2589–98. Epub 2008/09/04. doi: 10.1158/1535-7163.MCT-08-0493 PMID: 18765823; PubMed Central PMCID: PMC2614316.

29. Conway T, Wazny J, Bromage A, Tymms M, Sooraj D, Williams ED, et al. Xenome: a tool for classifying reads from xenograft samples. Bioinformatics. 2012; 28(12):i172–8. Epub 2012/06/13. doi: 10.1093/bioinformatics/bts236 PMID: 22689758; PubMed Central PMCID: PMC3571868.

30. Li H. Aligning sequence reads, clone sequences and assembly contigs with BWA-MEM. arXiv:13033997 [q-bio.GN]. 2013. arXiv:1303.3997 [q-bio.GN].

31. Li H, Handsaker B, Wysoker A, Fennell T, Ruan J, Homer N, et al. The Sequence Alignment/Map format and SAMtools. Bioinformatics. 2009; 25(16):2078–9. Epub 2009/06/10. doi: 10.1093/bioinformatics/btp352 PMID: 19505943; PubMed Central PMCID: PMC2723002.

32. Banerji U, Sain N, Sharp SY, Valenti M, Asad Y, Ruddle R, et al. An in vitro and in vivo study of the combination of the heat shock protein inhibitor 17-allylamino-17-demethoxygeldanamycin and carboplatin in human ovarian cancer models. Cancer Chemother Pharmacol. 2008; 62(5):769–78. Epub 2008/01/15. doi: 10.1007/s00280-007-0662-x PMID: 18193424.

33. Nemati F, Livartowski A, De Cremoux P, Bourgeois Y, Arvelo F, Pouillart P, et al. Distinctive potentiating effects of cisplatin and/or ifosfamide combined with etoposide in human small cell lung carcinoma xenografts. Clin Cancer Res. 2000; 6(5):2075–80. Epub 2000/05/18. PMID: 10819335.

34. Paine GD, Taylor CW, Lopez MH, Johnson CS, Capizzi RL. Effects of amifostine and paclitaxel on growth of human ovarian carcinoma xenografts in the severe combined immune-deficient mouse: preliminary results. Semin Oncol. 1996; 23(4 Suppl 8):35–9. Epub 1996/08/01. PMID: 9783664.

35. Press JZ, Kenyon JA, Xue H, Miller MA, De Luca A, Miller DM, et al. Xenografts of primary human gynecologic tumors grown under the renal capsule of NOD/SCID mice show genetic stability during serial transplantation and respond to cytotoxic chemotherapy. Gynecol Oncol. 2008; 110(2):256–64. Epub 2008/03/13. doi: 10.1016/j.ygyno.2008.03.011 PMID: 18547621.

36. Piura B, Rabinovich A, Yanai-Inbar I, Cohen Y, Gleizerman M. Primary sarcoma of the ovary: report of five cases and review of the literature. Eur J Gynaecol Oncol. 1998; 19(3):257–61. Epub 1998/06/26. PMID: 9641226.

37. Storer BE. Design and analysis of phase I clinical trials. Biometrics. 1989; 45(3):925–37. Epub 1989/09/01. PMID: 2790129.

38. Weroha SJ, Becker MA, Enderica-Gonzalez S, Harrington SC, Oberg AL, Maurer MJ, et al. Tumorgrafts as in vivo surrogates for women with ovarian cancer. Clin Cancer Res. 2014; 20(5):1288–97. Epub 2014/01/09. doi: 10.1158/1078-0432.CCR-13-2611079-0432.CCR-13-2611 [pii]. PMID: 24389046; PubMed Central PMCID: PMC3947430.

39. Sandhu SK, Schelman WR, Wilding G, Moreno V, Baird RD, Miranda S, et al. The poly(ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: a phase 1 dose-escalation trial. Lancet Oncol. 2013; 14(9):882–92. Epub 2013/07/03. doi: 10.1016/S1470-2045(13)70240-7 PMID: 23810788.

40. Audeh MW, Carmichael J, Penson RT, Friedlander M, Powell B, Bell-McGuinn KM, et al. Oral poly (ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial. Lancet. 2010; 376(9737):245–51. Epub 2010/07/09. doi: 10.1016/S0140-6736(10)60983-8 PMID: 20609468.

41. Hidalgo M, Bruckheimer E, Rajeshkumar NV, Garrido-Laguna I, De Oliveira E, Rubio-Viqueira B, et al. A pilot clinical study of treatment guided by personalized tumorgrafts in patients with advanced cancer. Molecular cancer therapeutics. 2011; 10(8):1311–6. Epub 2011/06/16. doi: 10.1158/1535-7163.MCT-11-0233 PMID: 21673092.
42. Topp MD, Hartley L, Cook M, Heong V, Boehm E, McShane L, et al. Molecular correlates of platinum response in human high-grade serous ovarian cancer patient-derived xenografts. Mol Oncol. 2014; 8(3):656–68. Epub 2014/02/02. doi: 10.1016/j.molonc.2014.01.008 PMID: 24560445.

43. Karachaliou N, Mayo C, Costa C, Magri I, Gimenez-Capitan A, Molina-Vila MA, et al. KRAS mutations in lung cancer. Clin Lung Cancer. 2013; 14(3):205–14. Epub 2012/11/06. doi: 10.1016/j.clcc.2012.09.007 PMID: 23122493.

44. Kodaz H, Hacibekiroglu I, Erdogan B, Turkmen E, Tozkir H, Albayrak D, et al. Association between specific KRAS mutations and the clinicopathological characteristics of colorectal tumors. Mol Clin Oncol. 2015; 3(1):179–84. Epub 2014/12/04. doi: 10.3892/mco.2014.448 PMID: 25469291; PubMed Central PMCID: PMC4251110.

45. Gamba S, Camaj P, Heinemann V, Laubender RP, Wang Y, Zhao Y, et al. Effect of KRAS exon 2 mutations on antitumor activity of afatinib and gefitinib. Anticancer Drugs. 2014. Epub 2014/12/17. doi: 10.1097/CAD.0000000000000196 PMID: 25514114.

46. Jones S, Stranksy M, McCord CL, Cerami E, Lagowski J, Kelly D, et al. Genomic analyses of gynecologic carcinosarcomas reveal frequent mutations in chromatin remodelling genes. Nat Commun. 2014; 5:5006. Epub 2014/09/23. doi: 10.1038/ncomms6006 PMID: 25233892.

47. Xu Y, Silver DF, Yang NP, Oflazoglu E, Hempling RE, Piver MS, et al. Characterization of human ovarian carcinomas in a SCID mouse model. Gynecol Oncol. 1999; 72(2):161–70. Epub 1999/02/18. S0090-8258(98)95238-6 [pii] doi:10.1006/gyno.1998.5238 PMID: 10021295.

48. Press JZ, Kenyon JA, Xue H, Miller MA, De Luca A, Miller DM, et al. Xenografts of primary human gynecological tumors grown under the renal capsule of NOD/SCID mice show genetic stability during serial transplantation and respond to cytotoxic chemotherapy. Gynecol Oncol. 2008; 110(2):256–64. Epub 2008/06/13. S0090-8258(08)00195-9 [pii] doi:10.1016/j.ygyno.2008.03.011 PMID: 18547621.

49. Lee CH, Xue H, Sutcliffe M, Gout PW, Huntsman DG, Miller DM, et al. Establishment of subrenal capsule xenografts of primary human ovarian tumors in SCID mice: potential models. Gynecol Oncol. 2005; 96(1):48–55. Epub 2004/12/14. S0090-8258(04)00739-5 [pii] doi:10.1016/j.ygyno.2004.09.025 PMID: 15989579.

50. Kortmann U, McAlpine JN, Xue H, Guan J, Ha G, Tully S, et al. Tumor growth inhibition by olaparib in BRCA2 germline-mutated patient-derived ovarian cancer tissue xenografts. Clin Cancer Res. 2011; 17(4):783–91. Epub 2010/11/26. doi: 10.1158/1078-0432.CCR-10-1382 PMID: 21097693.

51. Elkas JC, Baldwin RL, Pegram M, Tseng Y, Sliammon D, Karlan BY. A human ovarian carcinoma murine xenograft model useful for preclinical trials. Gynecol Oncol. 2002; 87(2):200–6. PMID: 12467452.

52. Bankert RB, Balu-Iyer SV, Odunsi K, Shultz LD, Kelleher RJ Jr, Barnas JL, et al. Humanized mouse model of ovarian cancer recapitulates patient solid tumor progression, ascites formation, and metastasis. PLoS One. 2011; 6(9):e24420. Epub 2011/09/22. doi: 10.1371/journal.pone.0024420 PMID: 21935406; PubMed Central PMCID: PMC3174163.

53. van Haaften-Day C, Russell P, Carr S, Wright L. Development and characterization of a human cell line from an ovarian mixed Mullerian tumor (carcinosarcoma). In Vitro Cell Dev Biol. 1988; 24(10):965–71. Epub 1988/10/01. PMID: 2903136.

54. Tentler JJ, Tan AC, Weekes CD, Jimeno A, Leong S, Pitts TM, et al. Patient-derived tumour xenografts as models for oncology drug development. Nat Rev Clin Oncol. 2012; 9(6):338–50. Epub 2012/04/18. doi: 10.1038/nrclinonc.2012.61 PMID: 22508029; PubMed Central PMCID: PMC3928688.